Presentation

Company Profile
Q-linea is an infection diagnostics company primarily developing instruments and disposables for rapid and reliable infection diagnostics. Its vision is to help save lives by ensuring that antibiotics continue to be an effective treatment for future generations. The lead product ASTar® is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. Q-linea was founded in 2008 and is headquartered in Uppsala, Sweden.

Recent highlights
A directed share issue was completed in June, raising approximately SEK 301 million in gross proceeds. This money will primarily be used for the commercialisation of ASTar®. In November 2020, Q-linea announced that they started development of a portable blood culture technology with the goal of shortening the time between sampling and correct antibiotic response. In March 2021, the company announced that its global sales partner Thermo Fisher Scientific had placed their first order on ASTar® instruments and consumables. In the same month, the company signed the first site for US study. In May 4th, the company announced that it received CE-IVD approval for ASTar®. In June, the company announced that it had initiated a US 510(k) clinical study for ASTar®.

Outlook
With the CE-IVD approval in hand and the clinical study for the US approval ongoing, the company’s focus lies on preparing for a launch that will be met with high demand, while at the same time ensuring the clinical trial is progressing according to plan, so that eventually the FDA approval can be achieved.